Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (19)
  • Aurora Kinase
    (6)
  • Autophagy
    (7)
  • FGFR
    (8)
  • FLT
    (53)
  • JAK
    (7)
  • PDGFR
    (16)
  • VEGFR
    (17)
  • c-Kit
    (19)
  • c-RET
    (7)
Filter
Search Result
Results for "

Cluster of differentiation antigen 135

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    56
    TargetMol | Activity
  • PROTAC Products
    1
    TargetMol | inventory
  • Natural Products
    2
    TargetMol | natural
Sorafenib
T0093L284461-73-0
Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6 22 90 15 20 20 57 58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Fostamatinib
T6115901119-35-5
Fostamatinib (R788)(IC50 of 41 nM), which is a prodrug of the active metabolite R406, is a Syk inhibitor. It does not work on Lyn.
  • $36
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Gilteritinib
T44091254053-43-4
Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Sorafenib tosylate
T0093475207-59-1
Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6 20 22 nM for Raf-1 VEGFR-3 B-Raf).
  • $37
In Stock
Size
QTY
TargetMol | Citations Cited
Cabozantinib
T2586849217-68-1
Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035 1.3 4.6 7 11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.
  • $39
In Stock
Size
QTY
TargetMol | Citations Cited
AKN-028
T385621175017-90-9In house
AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.
  • $53
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Cabozantinib hydrochloride
T51641817759-42-4
Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).
  • $37
In Stock
Size
QTY
4SC-203
T9473895533-09-2In house
4SC-203 is a multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs).
  • $68
In Stock
Size
QTY
AST 487
T4053630124-46-8
AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.
  • $31
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Pacritinib
T6020937272-79-2
Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
Amuvatinib
T2516850879-09-3
Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
  • $44
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Sitravatinib
T43491123837-84-2
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα β, PDGFR, and Axl.
  • $47
In Stock
Size
QTY
TargetMol | Citations Cited
FLT3-IN-3
T112982229050-90-0
FLT3-IN-3 is an effective FLT3 inhibitor, and the IC50s of FLT3 WT and FLT3 D835Y are 13 and 8 nM, respectively.
  • $109
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Quizartinib
T2066950769-58-1
Quizartinib (AC220) is an inhibitor of FLT3 (Kd: 1.6 nM) and demonstrates high selectivity for FLT3 when tested against a panel of 227 additional kinases.
  • $53
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Crenolanib
T2677670220-88-9
Crenolanib (ARO 002) is an orally bioavailable type III tyrosine kinases inhibitor of PDGFRα β and FLT3 (IC50s: 11, 3.2, and 4 nM).
  • $53
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
R406
T6174841290-81-1
R406 (R-406 besylate) is an effective Syk inhibitor (IC50: 41 nM) and shows no effects on Lyn.
  • $40
In Stock
Size
QTY
TargetMol | Citations Cited
AT9283
T3068896466-04-9
AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Rebastinib
T26401020172-07-9
DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit. Rebastinib aimed at the Angiopoietin2-Tie2 pathway.
  • $40
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
AC710
TQ02351351522-04-7
AC710 is a potent PDGFR inhibitor with Kds of 0.6 nM for FLT3, 1 nM for KIT, 1.57 nM for CSF1R, 1.3 nM for PDGFRα, and 1 nM for PDGFRβ.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
ATH686
T7673853299-52-2
ATH686 is an potent and selective Inhibitor of FLT3.
  • $65
In Stock
Size
QTY
TargetMol | Inhibitor Sale
KG5
T41003877874-85-6
KG5 is a dual allosteric inhibitor of PDGFRβ and B-Raf with a Kd of 520 nM and 300 nM for PDGFRβ and PDGFRα. KG5 inhibits FLT3, KIT, and c-Raf with anticancer and antiangiogenic activities.
  • $29
In Stock
Size
QTY
TargetMol | Inhibitor Sale
AZD2932
T1836883986-34-3
AZD2932 is a potent, multi-targeted kinase inhibitor of VEGFR2, PDGFβ, Flt-3, and c-Kit.
  • $33
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Merestinib
T34551206799-15-6
Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. Merestinib electively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing the constitutively activated c-Met protein.
  • $45
In Stock
Size
QTY
TargetMol | Inhibitor Sale
MRX-2843
T161441429882-07-4
MRX-2843 (UNC2371) is a potent and orally active inhibitor of MERTK and FLT3(IC50s of 1.3 nM and 0.64 nM, respectively).
  • $59
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Crotonoside
T6S00331818-71-9
1. Crotonoside (Isoguanosine) has much more active than adenosine in reducing the blood pressure in rabbits and cats, in decreasing the tone of isolated intestinal strips of the rabbit, guinea pig and hamster and in stimulating the isolated uterus of guinea pigs and hamsters. 2. Crotonoside inhibits the growth of S-18 and Ehrlich solid tumor in mice at the optimal doses of 96 mg kg day x 12 and 48 mg kg day x 12, with 1-T C values of 65% and 6%, respectively.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Tyrphostin AG1296
T6711146535-11-7
Tyrphostin AG1296 (Tyrphostin AG 1296) is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TCS 359
T6138301305-73-7
TCS 359 (FLT3 Inhibitor) is a potent FLT3 inhibitor with IC50 of 42 nM.
  • $31
In Stock
Size
QTY
TargetMol | Inhibitor Sale
R406 free base
T2467841290-80-0
R406 free base (R406 (free base)) is a potent Syk inhibitor.
  • $39
In Stock
Size
QTY
AMG 925
T67561401033-86-0
AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CCT241736
T44281402709-93-6
CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3, CCT241736, an advanced analog of CCT137690, is a preclinical development candidate for the treatment of human malignancies, and in particular AML in adults and children.
  • $55
In Stock
Size
QTY
TG101209
T3065936091-14-4
TG101209 is a selective JAK2 inhibitor with an IC50 of 6 nM.
  • $40
In Stock
Size
QTY
Linifanib
T2514796967-16-3
Linifanib (AL-39324) (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and PDGFRβ (IC50: 66 nM). Linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3).
  • $43
In Stock
Size
QTY
UNC2025
T70071429881-91-3
UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl and Tyro3.
  • $33
In Stock
Size
QTY
Altiratinib
T20541345847-93-9
Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with an HGF antagonist in vitro.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Sale
G-749
T26201457983-28-6
G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
  • $40
In Stock
Size
QTY
ENMD-2076
T2358934353-76-1
ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.
  • $47
In Stock
Size
QTY
TargetMol | Inhibitor Sale
BPR1J-097
T22721327167-19-0
BPR1J-097) is a novel FLT-3 inhibitor(IC50: 11±7 nM) with promising in vivo anti-tumor activities. It also inhibits FLT-3 D835Y (IC50: 3 nM).
  • $50
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Gandotinib
T26381229236-86-5
LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM). The selectivity is higher 8- and 20-fold than JAK1 and JAK3.
  • $47
In Stock
Size
QTY
PF 477736
T6028952021-60-2
PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.
  • $45
In Stock
Size
QTY
(E/Z)-Zotiraciclib
T21503937270-47-8
(E Z)-Zotiraciclib ((E Z)-TG02) effectively inhibits CDK2, JAK2, and FLT3 with IC50s of 13 nM, 73 nM, and 56 nM, respectively.
  • $38
In Stock
Size
QTY
KW-2449
T23411000669-72-6
KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 (IC50: 6.6 nM), modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R, EGFR.
  • $33
In Stock
Size
QTY
Ripretinib
T84821442472-39-0
Ripretinib (DCC-2618) is an orally bioavailable inhibitor of (KIT) and (PDGFRA).
  • $68
In Stock
Size
QTY
Dovitinib lactate hydrate
T6479915769-50-5
Dovitinib lactate hydrate (TKI258) is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3 c-Kit) with IC50 of 1 nM 2 nM, also potent to class IV (FGFR1 3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4.
  • $50
In Stock
Size
QTY
CHIR-124
T6350405168-58-3
CHIR-124 is an effective Chk1 inhibitor (IC50: 0.3 nM). It has 2, 000-fold selectivity against Chk2, 500- to 5, 000-fold less activity against Cdc2 and CDK2/4.
  • $35
In Stock
Size
QTY
TargetMol | Inhibitor Sale
FLT3-IN-2
T1938923562-23-6
FLT3-IN-2 is an FLT3 inhibitor (IC50<1 μM).
  • $36
In Stock
Size
QTY
TargetMol | Inhibitor Sale
FN-1501
T153351429515-59-2
FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively). FN-1501 also has anticancer activity.
  • $84
In Stock
Size
QTY
Fostamatinib Disodium
T26051025687-58-4
Fostamatinib Disodium (R788 Disodium) is an orally available Syk kinase inhibitor with potential anti-inflammatory and immunomodulatory activities.
  • $39
In Stock
Size
QTY
Dovitinib
T6289405169-16-6
Dovitinib (CHIR-258) (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3 c-Kit, IC50: 1 2 nM), also effective to class IV (FGFR1 3) and class V (VEGFR1-4) RTKs (IC50: 8-13 nM), less potent to EGFR, InsR, EphA2, c-Met, IGF-1R, Tie2, and HER2.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Quizartinib HCl
T714001132827-21-4
Quizartinib, also know as AC220 and AC010220, is an orally available FLT3 / STK1 inhibitor with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.
  • $1,520
1-2 weeks
Size
QTY
Isoguanosine
TNU0026359436-55-8
Iso-guanosine derivative
  • Inquiry Price
7-10 days
Size
QTY